RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?

Susceptibility to ankylosing spondylitis (AS) is polygenic with more than 100 genes identified to date. These include HLA-B27 and the aminopeptidases (ERAP1, ERAP2, and LNPEPS), which are involved in antigen processing and presentation to T-cells, and several genes (IL23R, IL6R, STAT3, JAK2, IL1R1/2...

Full description

Bibliographic Details
Main Authors:	Matteo Vecellio, Carla J. Cohen, Amity R. Roberts, Paul B. Wordsworth, Tony J. Kenna
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2019-01-01
Series:	Frontiers in Immunology
Subjects:	ankylosing spondylitis inflammation functional genomics autoimmunity therapy
Online Access:	https://www.frontiersin.org/article/10.3389/fimmu.2018.03132/full

id	doaj-855247b1718044fb952c68a8775d807c
record_format	Article
spelling	doaj-855247b1718044fb952c68a8775d807c2020-11-25T00:21:32ZengFrontiers Media S.A.Frontiers in Immunology1664-32242019-01-01910.3389/fimmu.2018.03132424898RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?Matteo Vecellio0Matteo Vecellio1Matteo Vecellio2Carla J. Cohen3Carla J. Cohen4Carla J. Cohen5Amity R. Roberts6Paul B. Wordsworth7Paul B. Wordsworth8Paul B. Wordsworth9Tony J. Kenna10Tony J. Kenna11Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United KingdomOxford Musculoskeletal Biomedical Research Unit, National Institute for Health Research, Oxford, United KingdomOxford Comprehensive Biomedical Research Centre, Botnar Research Centre, National Institute for Health Research, Nuffield Orthopaedic Centre, Oxford, United KingdomNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United KingdomOxford Musculoskeletal Biomedical Research Unit, National Institute for Health Research, Oxford, United KingdomOxford Comprehensive Biomedical Research Centre, Botnar Research Centre, National Institute for Health Research, Nuffield Orthopaedic Centre, Oxford, United KingdomDunn School of Pathology, University of Oxford, Oxford, United KingdomNuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United KingdomOxford Musculoskeletal Biomedical Research Unit, National Institute for Health Research, Oxford, United KingdomOxford Comprehensive Biomedical Research Centre, Botnar Research Centre, National Institute for Health Research, Nuffield Orthopaedic Centre, Oxford, United KingdomTranslational Research Institute, Princess Alexandra Hospital, Brisbane, QLD, AustraliaFaculty of Health, Institute of Health and Biomedical Innovation, Queensland University of Technology, Brisbane, QLD, AustraliaSusceptibility to ankylosing spondylitis (AS) is polygenic with more than 100 genes identified to date. These include HLA-B27 and the aminopeptidases (ERAP1, ERAP2, and LNPEPS), which are involved in antigen processing and presentation to T-cells, and several genes (IL23R, IL6R, STAT3, JAK2, IL1R1/2, IL12B, and IL7R) involved in IL23 driven pathways of inflammation. AS is also strongly associated with polymorphisms in two transcription factors, RUNX3 and T-bet (encoded by TBX21), which are important in T-cell development and function. The influence of these genes on the pathogenesis of AS and their potential for identifying drug targets is discussed here.https://www.frontiersin.org/article/10.3389/fimmu.2018.03132/fullankylosing spondylitisinflammationfunctional genomicsautoimmunitytherapy
collection	DOAJ
language	English
format	Article
sources	DOAJ
author	Matteo Vecellio Matteo Vecellio Matteo Vecellio Carla J. Cohen Carla J. Cohen Carla J. Cohen Amity R. Roberts Paul B. Wordsworth Paul B. Wordsworth Paul B. Wordsworth Tony J. Kenna Tony J. Kenna
spellingShingle	Matteo Vecellio Matteo Vecellio Matteo Vecellio Carla J. Cohen Carla J. Cohen Carla J. Cohen Amity R. Roberts Paul B. Wordsworth Paul B. Wordsworth Paul B. Wordsworth Tony J. Kenna Tony J. Kenna RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy? Frontiers in Immunology ankylosing spondylitis inflammation functional genomics autoimmunity therapy
author_facet	Matteo Vecellio Matteo Vecellio Matteo Vecellio Carla J. Cohen Carla J. Cohen Carla J. Cohen Amity R. Roberts Paul B. Wordsworth Paul B. Wordsworth Paul B. Wordsworth Tony J. Kenna Tony J. Kenna
author_sort	Matteo Vecellio
title	RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?
title_short	RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?
title_full	RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?
title_fullStr	RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?
title_full_unstemmed	RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?
title_sort	runx3 and t-bet in immunopathogenesis of ankylosing spondylitis—novel targets for therapy?
publisher	Frontiers Media S.A.
series	Frontiers in Immunology
issn	1664-3224
publishDate	2019-01-01
description	Susceptibility to ankylosing spondylitis (AS) is polygenic with more than 100 genes identified to date. These include HLA-B27 and the aminopeptidases (ERAP1, ERAP2, and LNPEPS), which are involved in antigen processing and presentation to T-cells, and several genes (IL23R, IL6R, STAT3, JAK2, IL1R1/2, IL12B, and IL7R) involved in IL23 driven pathways of inflammation. AS is also strongly associated with polymorphisms in two transcription factors, RUNX3 and T-bet (encoded by TBX21), which are important in T-cell development and function. The influence of these genes on the pathogenesis of AS and their potential for identifying drug targets is discussed here.
topic	ankylosing spondylitis inflammation functional genomics autoimmunity therapy
url	https://www.frontiersin.org/article/10.3389/fimmu.2018.03132/full
work_keys_str_mv	AT matteovecellio runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT matteovecellio runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT matteovecellio runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT carlajcohen runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT carlajcohen runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT carlajcohen runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT amityrroberts runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT paulbwordsworth runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT paulbwordsworth runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT paulbwordsworth runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT tonyjkenna runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy AT tonyjkenna runx3andtbetinimmunopathogenesisofankylosingspondylitisnoveltargetsfortherapy
_version_	1725362252364644352

RUNX3 and T-Bet in Immunopathogenesis of Ankylosing Spondylitis—Novel Targets for Therapy?

Similar Items